These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 36791472)

  • 1. Flashback Foreword: Gefitinib in Non-Small-Cell Lung Cancer: The IDEAL 1 Trial.
    Stinchcombe TE
    J Clin Oncol; 2023 Feb; 41(6):1159-1160. PubMed ID: 36791472
    [No Abstract]   [Full Text] [Related]  

  • 2. Knockout of lncRNA UCA1 inhibits drug resistance to gefitinib via targeting STAT3 signaling in NSCLC.
    Zhang B; Wang H; Wang Q; Xu J; Jiang P; Li W
    Minerva Med; 2019 Jun; 110(3):273-275. PubMed ID: 30784252
    [No Abstract]   [Full Text] [Related]  

  • 3. [Acute lung injury caused by mistaking high dose of gefitinib: a case report].
    Qiu MH; Yu PF; Zou SC
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 May; 39(5):371-372. PubMed ID: 34074085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib therapy for non-small cell lung cancer.
    Birnbaum A; Ready N
    Curr Treat Options Oncol; 2005 Jan; 6(1):75-81. PubMed ID: 15610717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial.
    Lim SW; Park S; Kim Y; Cho JH; Park SE; Lee H; Kim HK; Kim SM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2018 Oct; 124():293-297. PubMed ID: 30268476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non-Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification.
    Gainor JF; Stevens SE; Willers H; Shih HA; Heist RS
    J Thorac Oncol; 2020 Jan; 15(1):e8-e10. PubMed ID: 31864558
    [No Abstract]   [Full Text] [Related]  

  • 7. Papulopustules and paronychia in a lung carcinoma.
    Thakur V; Daroach M; Kumaran MS
    Eur J Intern Med; 2019 Apr; 62():e5-e6. PubMed ID: 30297249
    [No Abstract]   [Full Text] [Related]  

  • 8. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
    Johnson DH; Arteaga CL
    J Clin Oncol; 2003 Jun; 21(12):2227-9. PubMed ID: 12748243
    [No Abstract]   [Full Text] [Related]  

  • 10. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
    Sun C; Gao W; Liu J; Cheng H; Hao J
    Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?
    Vasile E; Tibaldi C; Falcone A
    Ann Oncol; 2009 Apr; 20(4):790-1. PubMed ID: 19264832
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
    Liu GF; Li XF; Yu SN; Miao YY; Zhang SH
    J Cell Physiol; 2019 Apr; 234(4):3445-3457. PubMed ID: 30374969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity.
    Kawamura T; Imamura CK; Kenmotsu H; Taira T; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mushiroda T; Takahashi T; Tanigawara Y
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):605-614. PubMed ID: 32040702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
    Price N; Belani C
    Clin Lung Cancer; 2005 Jan; 6(4):214-6. PubMed ID: 15694012
    [No Abstract]   [Full Text] [Related]  

  • 15. Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options.
    William WN; Gold KA; Kim ES
    Ann Oncol; 2009 Sep; 20(9):1455-1457. PubMed ID: 19704160
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
    Li WQ; Li LY; Chai J; Cui JW
    Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
    Nishio M; Kato T; Niho S; Yamamoto N; Takahashi T; Nogami N; Kaneda H; Fujita Y; Wilner K; Yoshida M; Isozaki M; Wada S; Tsuji F; Nakagawa K
    Cancer Sci; 2020 May; 111(5):1724-1738. PubMed ID: 32159882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approved use of gefitinib.
    Lyle J
    Am J Health Syst Pharm; 2004 Oct; 61(19):2008; author reply 2008. PubMed ID: 15509120
    [No Abstract]   [Full Text] [Related]  

  • 19. A Case of Small Cell Lung Cancer Transformation from EGFR-Mutant Lung Adenocarcinoma with Primary Resistance to Gefitinib.
    Chu X; Li Y; Zhu Z
    J Thorac Oncol; 2018 Oct; 13(10):e211-e214. PubMed ID: 30244858
    [No Abstract]   [Full Text] [Related]  

  • 20. [Gefitinib in non-small cell lung cancer].
    Nakagawa K
    Nihon Rinsho; 2004 Jul; 62(7):1312-20. PubMed ID: 15283149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.